Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Common Share (Tables)

Net Loss per Common Share (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of computation of earnings per share attributable to common stockholders

The following table sets forth the computation of earnings per share attributable to common stockholders for the quarter ended March 31, 2019 (amounts in thousands except share and per share data):


	Three Months Ended March 31,
	2019
Net income attributable to common stockholders	$	1,392

Weighted average shares outstanding - basic		48,506,994
Preferred stock, Series A		1,000,000
Stock options		378,835
Warrants		60,000
Unvested restricted stock		12,622,076
Unvested restricted stock units		1,243,231
Weighted average shares outstanding - diluted		63,811,136

Per share data:
Basic	$	0.03
Diluted	$	0.02

Schedule of diluted weighted average shares outstanding

The following shares of potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive for the three months ended March 31, 2020:


		March 31, 2020
Warrants to purchase Common Stock		773,234
Opus warrants to purchase Common Stock		1,880,000
Options to purchase Common Stock		1,210,502
Convertible Preferred Stock		1,706,208
Unvested Restricted Stock		14,307,564
Unvested Restricted Stock Units		487,996
Total		20,365,504